Laboratory testing for coagulation factor deficiencies and inhibitors is important for diagnosing and monitoring inherited and acquired coagulopathies and for evaluating the causes of coagulation ...

Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by low levels of the blood protein called factor 9. Factor 9 is a specialized protein necessary for blood ...

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...

Centessa Pharma's SerpinPC, a subcutaneous biologic inhibitor, shows promising results in reducing bleeding rates in hemophilia B, with a favorable safety profile. Despite the stock doubling in value, ...

The coagulation cascade is a finely balanced system essential for maintaining haemostasis, yet its disruption can lead to either a propensity for bleeding or an increased risk of clot formation.